Toxicity, pharmacokinetics, andin vivoefficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy
Source abstract
Abstract
Based on our previous work on the PLGA nanoparticles modified with biotinylated chitosan (Bio-CS-PLGA NPs), we further studied the stability, toxicity, pharmacokinetics, and in vivo efficacy. The safety of NPs was studied through single-dose toxicity test in mice, and the result showed that NPs were well tolerated at the dose of 300 mg/kg. Compared with the free EPB group, the NPs group exhibited higher plasma drug concentration, longer half-life time. EPB-loaded NPs significantly inhibited the tumor growth compared to free EPB. All results suggested that Bio-CS-PLGA NPs were stable, safe, and showed a promising potential on targeted drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Research Center of Stem Cell and Biotherapy Technology, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China;
Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, Tianjin, China;
Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Funding
The National Natural Sciences Foundation · The Key Technologies R&D Program of Henan Province
References (29)
Show source-provided references
1. 10.1016/j.toxlet.2016.01.01810.1016/j.toxlet.2016.01.018 ↗
2. 10.1016/B978-0-12-407173-5.00002-910.1016/B978-0-12-407173-5.00002-9 ↗
3. 10.2174/1573413711309666011310.2174/15734137113096660113 ↗
4. 10.1016/j.colsurfb.2015.11.03310.1016/j.colsurfb.2015.11.033 ↗
5. 10.1016/j.colsurfb.2009.05.02010.1016/j.colsurfb.2009.05.020 ↗
6. 10.1021/nn900002m10.1021/nn900002m ↗
7. 10.3109/21691401.2014.95510810.3109/21691401.2014.955108 ↗
8. 10.1016/j.echo.2013.10.00810.1016/j.echo.2013.10.008 ↗
9. 10.2165/00003088-200342050-0000210.2165/00003088-200342050-00002 ↗
10. 10.1016/j.carbpol.2015.12.03110.1016/j.carbpol.2015.12.031 ↗
11. 10.1002/jps.2387510.1002/jps.23875 ↗
12. 10.1016/j.biomaterials.2014.05.04010.1016/j.biomaterials.2014.05.040 ↗
13. 10.1016/j.nano.2014.08.00410.1016/j.nano.2014.08.004 ↗
14. 10.1016/j.colsurfb.2012.10.06310.1016/j.colsurfb.2012.10.063 ↗
15. 10.1016/j.phrs.2016.03.00610.1016/j.phrs.2016.03.006 ↗
16. Moghimi SM · Pharmacol Rev · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
17. 10.1002/jps.2466610.1002/jps.24666 ↗
18. 10.1126/science.111439710.1126/science.1114397 ↗
19. 10.1016/j.ijpharm.2013.06.03710.1016/j.ijpharm.2013.06.037 ↗
20. 10.1016/j.toxlet.2008.01.02010.1016/j.toxlet.2008.01.020 ↗
21. 10.1016/j.jconrel.2009.10.03210.1016/j.jconrel.2009.10.032 ↗
22. 10.3109/21691401.2014.93445610.3109/21691401.2014.934456 ↗
23. 10.3109/10717544.2010.49025010.3109/10717544.2010.490250 ↗
24. 10.1016/j.addr.2013.08.01210.1016/j.addr.2013.08.012 ↗
25. 10.1016/j.addr.2007.11.00710.1016/j.addr.2007.11.007 ↗
26. 10.1016/j.carbpol.2016.04.04110.1016/j.carbpol.2016.04.041 ↗
27. 10.1016/j.ejps.2012.04.01110.1016/j.ejps.2012.04.011 ↗
28. 10.1016/j.jconrel.2014.12.02210.1016/j.jconrel.2014.12.022 ↗
29. 10.1016/j.biomaterials.2013.11.08610.1016/j.biomaterials.2013.11.086 ↗